With your help, the AAPP Foundation can improve access to effective and compassionate care for individuals living with mental illness. This will be accomplished through our initiatives including research, scholarship, and practitioner development of psychiatric pharmacists.
No summary available
Our Mission As the philanthropic arm of AAPP, our mission is to advance the psychiatric pharmacy profession by supporting research, scholarship, and practitioner development. The Foundation’s mission complements that of our affiliated association, the American Association of Psychiatric Pharmacists (AAPP), which focuses on serving psychiatric pharmacists and aspiring psychiatric pharmacists and advancing their reach and practice.
AAPP has committed over $500,000 to directly support research related to the impact of psychiatric pharmacists on patient care through the AAPP Foundation. The commitment has already funded two major prospective research projects.
The mission of the American Association of Psychiatric Pharmacists (AAPP) is to advance the reach and practice of psychiatric pharmacy and serve as the voice of the specialty to improve the public's mental health care. Innovative quality improvement projects that support the integration of psychiatric pharmacists into mental health care teams are critical for the advancement of the profession.
No summary available
ASAM is recruiting experts to help develop updated clinical guidance on integrating tobacco use disorder interventions into addiction treatment. Opportunities are available on the writing group, education faculty team, and as field reviewers. Applications are due August 12.
Fewer adolescents reported using tobacco, alcohol, marijuana, and binge drinking.
Risks rose through year 5 in youths, but were seen after even just 1 year.
Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older.
Families desperately need support too.
This study of US youths found that year-to-year elevations in self-reported PSMU were directly associated with ADHD symptoms during mid-adolescence, particularly among males; reverse associations of ADHD symptoms with later PSMU were small in magnitude and sporadic.
This PhenX Toolkit SURWG process resulted in a new Substance Use Recovery Specialty Collection of recommended protocols with specific multidimensional applicability.
By gaining an understanding of the populations benefiting from these services, breadth of services provided, and the costs required to address this barrier to care, we may more effectively inform decision-makers on the resources needed to link and retain individuals in treatment.
This study illuminated reasons for not carrying naloxone, primarily related to stigma, discomfort with administration, or a lack of awareness/risk perception for an opioid-related overdose.
This study found no evidence any individual route of administration was associated with higher heroin overdose risk; instead, use of a single route tended to be associated with lower overdose odds than use of multiple routes.
Results suggest acceptability of a device for overdose detection and naloxone administration among PWUO and the addiction workforce, with more acceptability for a wearable versus implantable device.
In this study of pharmacies across the US, same-day naloxone availability and price remained uneven following OTC approval.
Among adults with AUD and T2D or obesity, initiation of newer GLP-1 RAs was associated with a lower observed risk of alcohol-related hospitalisation.
This paper briefly outlines the scientific rationale for brain circuit–based care, reviews the evidence for key interventions, and identifies barriers to implementation within public systems.
GTMRx submitted comments on NCQA’s Advanced Primary Care (APC) Accreditation standards, urging stronger recognition of medication optimization as a core component of high-quality, team-based primary care. AAPP is a supporter of GTMRx. The comments recommend incorporating comprehensive medication management throughout the standards and highlight the value of integrating clinical pharmacists into primary care teams to improve patient outcomes, safety, and overall healthcare value.
The study found that compared to 2014, burnout is higher among pharmacy practice faculty.
The FDA has approved centanafadine (Simtriyo), the first and only norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) for the treatment of ADHD in adults and children ages 6 and older weighing at least 20 kg. The approval was based on four Phase 3 clinical trials showing statistically significant and clinically meaningful improvements in ADHD symptoms. Centanafadine is expected to become available later this year following U.S. Drug Enforcement Administration (DEA) scheduling.
On July 27, the Substance Abuse and Mental Health Services Administration (SAMHSA) released the 2025 National Survey on Drug Use and Health (NSDUH) results. This survey provides insights into the experiences of U.S. residents experiencing mental health and substance use disorders.
No summary available